Vai al contenuto principale
xMedica

NCT07784725ClinicalTrials.gov

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity Without Type 2 Diabetes Mellitus (SELENE 1)

In reclutamentoAccetta partecipanti ora, secondo la scheda del registro.
Contatta questo studio

In breve

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

Fase 32500 partecipanti ricercati220 centri16 paesi

Categorie

Registrato in 1 registro

Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.

Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.

Ti interessa questo studio?

Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 6 days after the recorded start)First posted 2026-08-25; recorded start 2026-08-19
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 212 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 2,500 participants (target), run at 220 sites, across 16 countries.

How this score is built
  • Enrolment34/40

    2,500 participants (target)

  • Site count25/25

    212 sites

  • Country count15/15

    16 countries

  • Planned duration8/10

    Planned over about 34 months

  • Sponsor scale10/10

    AstraZeneca has led 1,017 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Sintesi

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

This is a Phase III, global, randomised, parallel-group, double-blind, multicentre study to assess the efficacy and safety of AZD6234 compared with placebo, administered SC once weekly in adults with obesity or overweight with at least one weight-related comorbidity without T2DM. Eligible participants will be randomized to either receive AZD6234 or matching placebo respectively.

Patologie

  • Obesity or Overweight

Idoneità

Idoneità
SessoTutti
Età18 Years – Nessun massimo
Volontari saniNo

Idoneità come riportata nel registro

Inclusion Criteria: * Males \& females (inclusive of all gender identities) age ≥18 years * BMI ≥30 kg/m2 OR BMI ≥27 kg/m2 with at least one of the following weight related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, heart failure, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, osteoarthritis of the knee, or stress urinary incontinence * Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation * History of at least one self-reported unsuccessful attempt to lose body weight in their lifetime Exclusion Criteria: * Obesity primarily caused by other endocrine disorders * History of Type 1 or Type 2 Diabetes Mellitus, HbA1c ≥6.5% (48 mmol/mol), and/or treatment with glucose-lowering agent(s) within 3 months prior to Screening * Significant hepatobiliary disease and/or any of the following results at Screening: * ALT ≥ 3.0 × ULN * AST ≥ 3.0 × ULN * TBL \> 1.5 × ULN (except for cases of known Gilbert's Syndrome) * Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation.

Idoneità in frasi semplici

I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.

Disegno dello studio

Disegno dello studio
Tipo di studioInterventistico
FaseFase 3
AssegnazioneRandomizzata
Modello di interventoPARALLEL
Finalità principaleTREATMENT
MascheramentoQUADRUPLE (4)
Arruolamento2500 partecipanti ricercati

Sponsor e collaboratori

  • AstraZeneca Sponsor

Bracci e interventi

  • AZD6234 Dose 1EXPERIMENTAL

    AZD6234 Dose 1

  • AZD6234 Dose 2EXPERIMENTAL

    AZD6234 Dose 2

  • PlaceboPLACEBO_COMPARATOR

    Matching placebo

Interventi

  • Farmaco Lenbelintide

    IMP injected subcutaneously, once a week. Unit dose strength as per CSP.

  • Farmaco Placebo

    Placebo matching IMP dose injected subcutaneously, once a week.

Esiti misurati

  1. Esito primario

    Percent change in body weight from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo in percent body weight change

    Orizzonte temporale 68 weeks

  2. Esito secondario

    Absolute change in weight (kg) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on absolute change in weight

    Orizzonte temporale 68 weeks

  3. Esito secondario

    Achievement of at least 5 % body weight loss from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo in body weight loss of at least 5%

    Orizzonte temporale 68 weeks

  4. Esito secondario

    Achievement of at least 10% body weight loss from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo in body weight loss of at least 10%

    Orizzonte temporale 68 weeks

  5. Esito secondario

    Change in waist circumference (cm) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on waist circumference change

    Orizzonte temporale 68 weeks

  6. Esito secondario

    Percent change in triglycerides from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on triglycerides percent change

    Orizzonte temporale 68 weeks

  7. Esito secondario

    Change in systolic blood pressure (mmHg) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on systolic blood pressure change

    Orizzonte temporale 68 weeks

  8. Esito secondario

    Percent change in fat mass from baseline at 68 weeks of treatment measured by DXA in the DXA Sub-Study subset

    Body Composition Sub-study: To evaluate the effect of AZD6234 as compared to placebo on body composition change in the DXA subset of participants

    Orizzonte temporale 68 weeks

Date

Date
Data di inizio19 agosto 2026 (effettiva)
Conclusione primaria11 agosto 2028 (stimata)
Conclusione21 maggio 2029 (stimata)
Prima pubblicazione25 agosto 2026 (effettiva)
Ultimo aggiornamento30 ottobre 2026
Risultati pubblicatiNon indicato nella scheda del registro
Stato verificato l'ultima voltaottobre 2026

«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.

Centri

76 centri stanno reclutando

Argentina

Argentina
StrutturaCittàStato o regioneStato
Research SiteBuenos AiresIn reclutamento
Research SiteBuenos AiresIn reclutamento
Research SiteCiudad de Buenos AiresIn reclutamento
Research SiteMendozaIn reclutamento
Research SiteRamos MejíaNon ancora in reclutamento
Research SiteRosarioIn reclutamento
Research SiteSan NicolásNon ancora in reclutamento

Australia

Australia
StrutturaCittàStato o regioneStato
Research SiteBotanyIn reclutamento
Research SiteCamberwellIn reclutamento
Research SiteCharlestownIn reclutamento
Research SiteSt AlbansIn reclutamento
Research SiteSt LeonardsIn reclutamento
Research SiteWaitaraIn reclutamento

Brazil

Brazil
StrutturaCittàStato o regioneStato
Research SiteBelo HorizonteNon ancora in reclutamento
Research SiteBrasíliaNon ancora in reclutamento
Research SiteCampinasNon ancora in reclutamento
Research SiteCampinasNon ancora in reclutamento
Research SiteCuritibaRitirato
Research SiteCuritibaNon ancora in reclutamento
Research SiteCuritibaNon ancora in reclutamento
Research SiteNatalNon ancora in reclutamento
Research SitePorto AlegreNon ancora in reclutamento
Research SiteRio de JaneiroNon ancora in reclutamento
Research SiteSão José dos CamposNon ancora in reclutamento
Research SiteSão PauloNon ancora in reclutamento

Bulgaria

Bulgaria
StrutturaCittàStato o regioneStato
Research SiteMontanaNon ancora in reclutamento
Research SitePlevenNon ancora in reclutamento
Research SitePlovdivIn reclutamento
Research SiteSofiaIn reclutamento
Research SiteSofiaIn reclutamento
Research SiteSofiaIn reclutamento
Research SiteVarnaNon ancora in reclutamento
Research SiteYambolIn reclutamento

Canada

Canada
StrutturaCittàStato o regioneStato
Research SiteBramptonOntarioIn reclutamento
Research SiteCalgaryAlbertaIn reclutamento
Research SiteGuelphOntarioIn reclutamento
Research SiteHamiltonOntarioIn reclutamento
Research SiteMississaugaOntarioIn reclutamento
Research SiteMonctonNew BrunswickIn reclutamento
Research SiteMontrealQuebecIn reclutamento
Research SiteNew WestminsterBritish ColumbiaIn reclutamento
Research SiteNorth YorkOntarioIn reclutamento
Research SiteQuébecQuebecIn reclutamento
Research SiteQuébecQuebecIn reclutamento
Research SiteSaint-Charles-BorroméeQuebecIn reclutamento
Research SiteScarborough VillageOntarioIn reclutamento
Research SiteSherbrookeQuebecIn reclutamento
Research SiteStoney CreekOntarioIn reclutamento
Research SiteStouffvilleOntarioIn reclutamento
Research SiteSurreyBritish ColumbiaRitirato

Nella scheda del registro sono indicati altri 170 centri.

Documenti dello studio

In questa scheda del registro non sono collegati documenti.

Modifiche nel tempo

  1. 30 ottobre 2026

    Centro aggiunto

    8 sites added (220 total)

    212220